Vimarsana
Biggest News Aggregation in the World

Glenn Corr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Glenn Corr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Glenn Corr Today - Breaking & Trending Today

CSPAN2 Book Discussion September 21, 2014 - Vimarsana News

CSPAN2 Book Discussion September 21, 2014

I was taking notes. Not like i was making but it turned out at the hand of our interview retired for several hours and when i got to build a given my credit card to pick up the tab, he said you really dont look anything like i expected. I thought you were paul. I immediately knew what it happened. There is another Ken Silverstein in West Virginia who writes a lot about the oil industry. He writes her trade industry publication and is very, very i would say more sympathetic to the industry and circumspect than i am. So i felt obliged to say i think theres been a misunderstanding. But because of...

Britain doubles down on the life-sciences industry - Vimarsana News

Britain doubles down on the life-sciences industry

The government vows to clear hurdles so the sector can flourish. Will it be enough? | Britain

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results - Vimarsana News

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability Shareholder commitment to TauRxrepresents a significant success story for UK-based life sciences research and development in areas of great unmet medical need TauRxwill present the Phase 3 findings at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco ABERDEEN, Scotland and SINGAPORE,...

Related Topics:
United KingdomCity OfSan FranciscoUnited StatesGlenn CorrPrnewswire Taurx Pharmaceuticals LtdUniversity Of AberdeenUnited Kingdom BasedClinical TrialsChief Operating OfficerChief Business OfficerJefferies HealthcareSubstantial Investment Of Usd119 Million Achieved By Taurx Througha Warrants Exercise Triggered The Announcement Lucidity Results In OctoberUpporting Hmtm Regulatory Submissions In UkUs And CanadaNd Preparation For Market Availability Shareholder Commitment To Taurxrepresentsa Significant Success Story Uk Based Life Sciences Research And Development In Areas Of Great Unmet Medical Need Taurxwill Present The Phase 3 Findings At Clinical Trials Alzheimer 39s Disease Ctad Conference On Wednesday0th November 2022N San Francisco AberdeenScotland And SingaporeNov 14022 Prnewswire Taurx Pharmaceuticals Ltd Isa Global Leader In Tau Based Research Alzheimer 39s Disease Ad Pathological Aggregation Of Correlates With Clinical Severity And Brain Atrophy It Hallmark The Recognised As An Important Potential Target For Treating Hmtm Is Oral InhibitorArgeting This Underlying Pathology Glenn CorrHief Operating Officer And Chief Business Said Quot We Appreciate The Continued Support Of Our Shareholders As Evidenced By Their Exercise Warrants This Representsa Firm Commitment To Mission 39 DiscoverNd Commercialise Innovative Products For The Diagnosis And Treatment Of Neurodegenerative Diseases Caused By Protein Aggregation 39 Beyond Funding Regulatory Submissions In UkHis Investment Will Also Advance Development Plans For Regulatory Approval In China Quot The Positive Outcome Of This Funding Round
TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results - Vimarsana News

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability Shareholder commitment to TauRxrepresents a significant success story for UK-based life sciences research and development in areas of great unmet medical need TauRxwill present the Phase 3 findings at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco ABERDEEN, Scotland and SINGAPORE,...

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results - Vimarsana News

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting...